They only get 50% of any Sublicense deal. But my understand, Eisai has the N/A and J&J has the rest of the world. So no more license deals.
If you wonder what the revenues mean to ASTX on Dacogen for aml, it's pretty simple. We already are selling 200M in dacogen for MDS, so the top tier is reached. Anything that J&J sells for aml, is all at 30%. Granted it will come in the quarterly numbers looking lower, but later sales in the year will all be at 30%.
Last year we had sales of Dacogen of $216M. So only 16M was treated with the 30% rate. Now after approval for aml, let's say MDS stays exactly the same and they sell an extra $50M in aml, so 2013 sales are $266M ($216 + 50M). ASTX see's the additional $50M extra treated with a 30% royality.